Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

F. Lansigan · SciRah

Researcher profile · Semantic Scholar

F. Lansigan

Share profile

F. Lansigan — researcher profile on SciRah

h-index: 29
Works: 202
Citations: 3,446

Most-cited papers

The Role of Autologous Stem Cell Transplantation in Patients With Nodal Peripheral T-Cell Lymphomas in First Complete Remission: Report From COMPLETE, a Prospective, Multicenter Cohort Study
Steven I. Park, S. Horwitz, F. Foss, L. Pinter-Brown +22 more
2019Cancer139 citations Open access
Semantic Scholar
Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma
J. Castillo, T. Guerrero-Garcia, F. Baldini, E. Tchernonog +15 more
2019British Journal of Haematology86 citations Open access
Semantic Scholar
Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions.
V. Orellana-Noia, Daniel R. Reed, A. McCook, J. Sen +49 more
2021Blood84 citations Open access
Semantic Scholar
Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era.
J. Gerson, E. Handorf, D. Villa, A. Gerrie +46 more
2019Journal of Clinical Oncology81 citations Open access
Semantic Scholar
Tumor lysis, adverse events, and dose adjustments in 297 venetoclax treated CLL in routine clinical practice
L. Roeker, C. Fox, T. Eyre, D. Brander +32 more
2019Clinical Cancer Research80 citations Open access
Semantic Scholar
Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen
Meghan C. Thompson, R. Harrup, Catherine C. Coombs, L. Roeker +34 more
2022Blood Advances53 citations Open access
Semantic Scholar
Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.
J. Sharman, D. Brander, A. Mato, N. Ghosh +15 more
2021The Lancet Haematology45 citations
Semantic Scholar
Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry
F. Lansigan, S. Horwitz, L. Pinter-Brown, S. Rosen +21 more
2019Acta Haematologica45 citations Open access
Semantic Scholar
Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics.
P. Torka, S. Kothari, S. Sundaram, Shao-Ying Li +28 more
2020Blood Advances39 citations Open access
Semantic Scholar
Phase 2 Study of the Safety and Efficacy of Umbralisib in Patients with CLL Who Are Intolerant to BTK or PI3Kδ Inhibitor Therapy.
A. Mato, N. Ghosh, S. Schuster, N. Lamanna +26 more
2020Blood38 citations Open access
Semantic Scholar
The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia
T. Eyre, L. Roeker, C. Fox, Satyen H Gohill +21 more
2019British Journal of Haematology27 citations Open access
Semantic Scholar
A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL.
A. Mato, L. Roeker, T. Eyre, C. Nabhan +34 more
2019Blood Advances25 citations Open access
Semantic Scholar
Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphoma
J. Abramson, Elizabeth Bengston, R. Redd, J. Barnes +12 more
2022Blood Advances24 citations Open access
Semantic Scholar
Checkpoint blockade treatment sensitises relapsed/refractory non‐Hodgkin lymphoma to subsequent therapy
N. Carreau, P. Armand, R. Merryman, R. Advani +21 more
2020British Journal of Haematology23 citations Open access
Semantic Scholar
MAGNIFY: Phase IIIb interim analysis of induction R2 followed by maintenance in relapsed/refractory indolent non-Hodgkin lymphoma.
D. Andorsky, M. Coleman, A. Yacoub, J. Melear +9 more
2019Journal of Clinical Oncology21 citations
Semantic Scholar
ENGINE: a Phase III randomized placebo controlled study of enzastaurin/R-CHOP as frontline therapy in high-risk diffuse large B-cell lymphoma patients with the genomic biomarker DGM1.
G. Nowakowski, Jun Zhu, Qing-Yuan Zhang, J. Brody +18 more
2020Future Oncology19 citations Open access
Semantic Scholar
Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma.
R. Merryman, N. Carreau, R. Advani, M. Spinner +29 more
2020The Oncologist15 citations Open access
Semantic Scholar
Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma
J. Gerson, E. Handorf, D. Villa, A. Gerrie +46 more
2023Blood Advances14 citations Open access
Semantic Scholar
Oncogenic Integration of Nucleotide Metabolism via Fatty Acid Synthase in Non-Hodgkin Lymphoma
Dashnamoorthy Ravi, A. Beheshti, N. Abermil, F. Lansigan +15 more
2021Frontiers in Oncology14 citations Open access
Semantic Scholar
Venetoclax Re-Treatment of Chronic Lymphocytic Leukemia (CLL) Patients after a Previous Venetoclax-Based Regimen
Meghan C. Thompson, J. Allan, K. Sail, B. Manzoor +22 more
202014 citations Open access
Semantic Scholar
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real‐world setting. A GIMEMA‐ERIC and US study
A. Cuneo, A. Mato, G. Rigolin, A. Piciocchi +43 more
2020Cancer Medicine14 citations Open access
Semantic Scholar
Hypertension treatment for patients receiving ibrutinib: a multicenter retrospective study
Laura Samples, J. Voutsinas, B. Fakhri, S. Khajavian +31 more
2024Blood Advances13 citations Open access
Semantic Scholar
Completed Induction Phase Analysis of Magnify: Phase 3b Study of Lenalidomide + Rituximab (R 2) Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
F. Lansigan, D. Andorsky, M. Coleman, A. Yacoub +10 more
2021Blood11 citations Open access
Semantic Scholar
Health Through Activity: Initial Evaluation of an In-Home Intervention for Older Adults With Cancer
K. Lyons, M. Bruce, Jay G. Hull, P. Kaufman +9 more
2019American Journal of Occupational Therapy11 citations
Semantic Scholar
Acute myeloid leukemia with hepatic infiltration presenting as obstructive jaundice
L. Walsh, Chao-jie Yuan, James T. Boothe, H. Conway +4 more
2021Leukemia Research Reports10 citations Open access
Semantic Scholar
Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation
N. Epperla, Ying Huang, A. Cashen, John L. Vaughn +21 more
2024Blood Advances9 citations Open access
Semantic Scholar
Effect of adding ublituximab to ibrutinib on PFS, ORR, and MRD negativity in previously treated high-risk chronic lymphocytic leukemia: Final results of the GENUINE phase III study.
J. Sharman, D. Brander, A. Mato, N. Ghosh +15 more
20209 citations
Semantic Scholar
Outcomes of Patients with Transformed Mycosis Fungoides: Analysis from a Prospective Multicenter US Cohort Study
F. Lansigan, S. Horwitz, L. Pinter-Brown, K. Carson +10 more
2020Clinical Lymphoma, Myeloma & Leukemia9 citations Open access
Semantic Scholar
Treatment Effectiveness of Venetoclax‐Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real‐World Study
Nilanjan Ghosh, T. Eyre, Jennifer R. Brown, N. Lamanna +29 more
2024American journal of hematology/oncology8 citations Open access
Semantic Scholar
Treatment Effectiveness with Venetoclax-Based Therapy after Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study
N. Ghosh, N. Lamanna, T. Eyre, Catherine C. Coombs +26 more
2023Blood8 citations Open access
Semantic Scholar
MAGNIFY phase IIIb interim analysis of induction R2 followed by maintenance in relapsed/refractory indolent NHL.
D. Andorsky, M. Coleman, A. Yacoub, J. Melear +10 more
20208 citations
Semantic Scholar
Lacutamab in Patients with Relapsed and Refractory Sèzary Syndrome: Results from the Tellomak Phase 2 Trial
M. Bagot, Youn H. Kim, L. Geskin, P. Ortiz-Romero +18 more
2023Blood7 citations Open access
Semantic Scholar
The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy
C. Ujjani, A. Mato, B. Hill, J. Allan +17 more
2020Blood and Lymphatic Cancer : Targets and Therapy7 citations Open access
Semantic Scholar
Patients with Relapsed/Refractory Marginal Zone Lymphoma in the MAGNIFY Phase IIIb Interim Analysis of Induction R2 Followed By Maintenance
M. Coleman, D. Andorsky, A. Yacoub, J. Melear +10 more
20207 citations
Semantic Scholar
Multicenter, Open-Label, Phase II Study of Bendamustine and Rituximab Followed by 90-Yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma (Fol-BRITe)
F. Lansigan, Cristiana A Costa, B. Zaki, Stephanie P. Yen +9 more
2019Clinical Cancer Research7 citations
Semantic Scholar
Lacutamab in patients with relapsed and refractory Sézary syndrome: Long term follow-up from the TELLOMAK phase 2 trial.
Pierluigi Porcu, M. Bagot, Youn H. Kim, C. Ram-Wolff +16 more
2025Journal of Clinical Oncology6 citations Open access
Semantic Scholar
Epstein-Barr Virus Infection-associated Hemophagocytic Lymphohistiocytosis
Pamela Contreras-Chavez, Andrea Anampa-Guzmán, Safwan Gaznabi, F. Lansigan
2020Cureus6 citations Open access
Semantic Scholar
Combined Modality Treatment With Brentuximab Vedotin and Radiation Therapy for Primary Cutaneous Anaplastic Large Cell Lymphoma: A Case Report
Erin G. Floyd, Timothy F. Burns, K. Linos, Robert E. LeBlanc +3 more
2019Journal of Hematology6 citations Open access
Semantic Scholar
Adenopathy and extensive skin patch overlying a plasmacytoma with unusual histologic findings in a patient with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes syndrome and Castleman disease
Alicia T. Dagrosa, Molly C E Cowdrey, Robert E. LeBlanc, F. Lansigan +2 more
2019Journal of cutaneous pathology6 citations
Semantic Scholar
Race and Ethnicity-Conscious Clinical Research Best Practices.
O. Barrett-Campbell, Maya Degroote, F. Lansigan
2022JAMA Oncology5 citations
Semantic Scholar
Safety of Mogamulizumab in Mycosis Fungoides and Sézary Syndrome: Final Results from the Phase 3 Mavoric Study
Youn H. Kim, M. Bagot, P. Zinzani, M. Duvic +66 more
2019Blood5 citations
Semantic Scholar
Lacutamab in Patients with Relapsed and/or Refractory Sézary Syndrome: Translational Analysis from the Tellomak Phase 2 Trial
M. Battistella, A. Gru, H. Moins-Teisserenc, M. Bagot +27 more
2024Blood4 citations
Semantic Scholar
P648: REAL-WORLD TREATMENT AND OUTCOMES OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) RECEIVING FIRST-LINE (1L) THERAPY IN THE NOVEL AGENT ERA: AN INTERNATIONAL STUDY
F. Lansigan, T. Eyre, N. Ghosh, B. Manzoor +25 more
2023HemaSphere4 citations Open access
Semantic Scholar
A Survey of Cancer Risk Behaviors, Beliefs, and Social Drivers of Health in New Hampshire and Vermont
T. Skipper, Julie E. Weiss, Heather A. Carlos, C. Gunn +6 more
2023Cancer Research Communications4 citations Open access
Semantic Scholar
A phase I trial of BNC105P and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia
Darcy B. Pooler, Dylan B Ness, A. Danilov, Bridget M Labrie +4 more
2022eJHaem4 citations Open access
Semantic Scholar
Unraveling subcutaneous panniculitis‐like T‐cell lymphoma: An association between subcutaneous panniculitis‐like T‐cell lymphoma, autoimmune lymphoproliferative syndrome, and familial hemophagocytic lymphohistiocytosis
Robert E. LeBlanc, F. Lansigan
2020Journal of cutaneous pathology4 citations
Semantic Scholar
Utilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United States
S. Huntington, P. Soulos, P. Barr, R. Jacobs +5 more
2019Blood4 citations Open access
Semantic Scholar
A PHASE 2 STUDY TO ASSESS THE SAFETY AND EFFICACY OF UMBRALISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO ARE INTOLERANT TO PRIOR BTK OR PI3K DELTA INHIBITOR THERAPY
A. Mato, S. J. Schuster, N. Lamanna, J. Pagel +22 more
2019Hematological Oncology4 citations
Semantic Scholar
A phase 2 study to assess the safety and efficacy of umbralisib (TGR-1202) in pts with CLL who are intolerant to prior BTK or PI3Kδ inhibitor therapy.
A. Mato, S. Schuster, N. Lamanna, I. Flinn +16 more
20184 citations
Semantic Scholar
Efficacy and safety results from the primary analysis of the pivotal summit trial: Bezuclastinib in adults with non-advanced systemic mastocytosis
Lindsay A. M. Rein, Nathan A. Boggs, P. Bose, Brian D. Modena +53 more
2025Blood3 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. Mato×13
Invite
A. Mato — researcher profile on SciRah
L. Roeker×12
Invite
L. Roeker — researcher profile on SciRah
A. Skarbnik×12
Invite
A. Skarbnik — researcher profile on SciRah
S. Schuster×11
Invite
S. Schuster — researcher profile on SciRah

×11

Invite

P. Barr — researcher profile on SciRah

Invite

D. Brander — researcher profile on SciRah

Invite

N. Lamanna — researcher profile on SciRah

Invite

C. Ujjani — researcher profile on SciRah

Invite

J. Allan — researcher profile on SciRah

Invite

M. Shadman — researcher profile on SciRah

Invite

J. Pagel — researcher profile on SciRah

Reem Karmali×7

Invite

Reem Karmali — researcher profile on SciRah